Immunological responses to pneumococcal vaccine in frail older people - PubMed (original) (raw)
Randomized Controlled Trial
. 2009 Mar 4;27(10):1628-36.
doi: 10.1016/j.vaccine.2008.11.098. Epub 2008 Dec 17.
Affiliations
- PMID: 19100304
- DOI: 10.1016/j.vaccine.2008.11.098
Randomized Controlled Trial
Immunological responses to pneumococcal vaccine in frail older people
I Ridda et al. Vaccine. 2009.
Erratum in
- Vaccine. 2009 Nov 5;27(47):6649
Abstract
Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone.
Aim: To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients.
Method: 241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable > or = 2.0 to 3.99-fold and strong > or = 4.0-fold increase).
Results: Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects.
Conclusions: Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.
Similar articles
- Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Miernyk KM, et al. Clin Infect Dis. 2009 Jul 15;49(2):241-8. doi: 10.1086/599824. Clin Infect Dis. 2009. PMID: 19522655 Clinical Trial. - Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA; PCV13 Infant Study Group. Bryant KA, et al. Pediatrics. 2010 May;125(5):866-75. doi: 10.1542/peds.2009-1405. Pediatrics. 2010. PMID: 20435707 Clinical Trial. - Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
Lin PL, Michaels MG, Green M, Mazariegos GV, Webber SA, Lawrence KS, Iurlano K, Greenberg DP. Lin PL, et al. Pediatrics. 2005 Jul;116(1):160-7. doi: 10.1542/peds.2004-2312. Pediatrics. 2005. PMID: 15995047 - Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
Dagan R. Dagan R. Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20. doi: 10.1111/j.1469-0691.2009.02726.x. Clin Microbiol Infect. 2009. PMID: 19366365 Review. - Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Knuf M, et al. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. Pediatr Infect Dis J. 2009. PMID: 19325452 Review.
Cited by
- Baseline Pneumococcal IgG Levels and Response to 23-Valent Pneumococcal Polysaccharide Vaccine among Adults from Beijing, China.
Zhou S, Lv M, Bai S, Chen W, Zhao W, Wang J, Zhang A, Li J, Xie H, Gao Y, Li D, Wu J. Zhou S, et al. Vaccines (Basel). 2023 Nov 29;11(12):1780. doi: 10.3390/vaccines11121780. Vaccines (Basel). 2023. PMID: 38140184 Free PMC article. - Memory T cell responses in seronegative older adults following SARS-CoV-2 vaccination.
Hafızoğlu M, Bas AO, Tavukçuoğlu E, Sahiner Z, Oytun MG, Ulutürk S, Yanık H, Doğu BB, Cankurtaran M, Esendağlı G, Akbıyık F, Çakır B, Ünal S, Halil MG. Hafızoğlu M, et al. Clin Immunol Commun. 2022 Dec;2:154-158. doi: 10.1016/j.clicom.2022.09.005. Epub 2022 Sep 29. Clin Immunol Commun. 2022. PMID: 38013969 Free PMC article. - Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making.
See KC. See KC. Vaccines (Basel). 2023 Apr 27;11(5):908. doi: 10.3390/vaccines11050908. Vaccines (Basel). 2023. PMID: 37243012 Free PMC article. Review. - Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign.
Meyers E, De Rop L, Deschepper E, Duysburgh E, De Burghgraeve T, Van Ngoc P, Digregorio M, Delogne S, Coen A, De Clercq N, Buret L, Coenen S, De Sutter A, Scholtes B, Verbakel JY, Cools P, Heytens S. Meyers E, et al. Eur J Gen Pract. 2023 Dec;29(2):2149732. doi: 10.1080/13814788.2022.2149732. Epub 2022 Nov 28. Eur J Gen Pract. 2023. PMID: 36440533 Free PMC article. - Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study.
Meyers E, Deschepper E, Duysburgh E, De Rop L, De Burghgraeve T, Van Ngoc P, Digregorio M, Delogne S, Coen A, De Clercq N, Buret L, Coenen S, Sutter A, Scholtes B, Verbakel JY, Cools P, Heytens S. Meyers E, et al. Viruses. 2022 Oct 26;14(11):2361. doi: 10.3390/v14112361. Viruses. 2022. PMID: 36366456 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources